Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
      • Neuroimmunology: To Sense and Protect
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • My alerts
  • Log in
  • Log out
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

The Epistatic Interrelationships of IL-1, IL-1 Receptor Antagonist, and the Type I IL-1 Receptor

Vera M. Irikura, Mouna Lagraoui and David Hirsh
J Immunol July 1, 2002, 169 (1) 393-398; DOI: https://doi.org/10.4049/jimmunol.169.1.393
Vera M. Irikura
Department of Biochemistry and Molecular Biophysics, College of Physicians and Surgeons, Columbia University, New York, NY 10032
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mouna Lagraoui
Department of Biochemistry and Molecular Biophysics, College of Physicians and Surgeons, Columbia University, New York, NY 10032
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Hirsh
Department of Biochemistry and Molecular Biophysics, College of Physicians and Surgeons, Columbia University, New York, NY 10032
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Mice lacking the gene for the IL-1R antagonist (IL-1ra) show abnormal development and homeostasis as well as altered responses to infectious and inflammatory stimuli. A reduction in the level of IL-1 signaling, either by deletion of the receptor or increased expression of IL-1ra, does not affect development or homeostasis, but does alter immune responses. In this study we use genetic epistasis to investigate the interdependence of selected genes in the IL-1 family in the regulation of these developmental and immunological processes. Deletion of the gene encoding the type I IL-1R (IL-1RI) is epistatic to deletion of the IL-1ra gene. Therefore, all functions of IL-1ra depend upon the presence of a functional receptor; there is no other target. Similarly, overexpression of the mRNA encoding the secreted form of IL-1ra is epistatic to deletion of the receptor antagonist, leaving the role of the intracellular splice variants of IL-1ra unknown. The abnormal development of IL-1ra-deficient mice is probably due to chronic overstimulation of the proinflammatory pathway via IL-1, but a clear single pathological defect is not apparent. These results support the model that the only essential function of IL-1ra in both health and disease is competitive inhibition of the IL-1RI.

The proinflammatory cytokine IL-1 is encoded by two different genes, IL-1α and IL-1β, which are evolutionarily related (1). Both IL-1α and IL-1β are synthesized as 31-kDa precursors that lack signal peptides. The mature agonists are 17-kDa proteins that elicit virtually identical biological responses. During signaling, IL-1 binds first to the type I receptor (IL-1RI3 or p80), and this complex then recruits the IL-1R accessory protein, a homologue of IL-1RI. Formation of the ternary IL-1 signaling receptor complex leads to high affinity binding and signal transduction (2). The third member of the IL-1 family of ligands is the IL-1R antagonist (IL-1ra) (reviewed in Ref. 3). It binds to the same receptors as the agonists, but does not elicit any detectable biological response, since the binary complex formed by IL-1ra bound to IL-1RI fails to recruit the IL-1R accessory protein and thus fails to transduce a signal (2).

A single gene encodes all isoforms of IL-1ra (Fig. 1⇓A). One is a secreted protein (sIL-1ra) of 17 kDa that has a canonical signal peptide. It is synthesized as a 20-kDa precursor, processed, and released from cells via the classical secretory pathway. The other isoforms of IL-1ra are intracellular; they lack a functional leader sequence and remain in the cytosol. The 18-kDa intracellular IL-1ra (icIL-1ra1) isoform arises via alternative splicing that removes the signal peptide. Intracellular IL-1ra2 contains an additional in-frame exon and has only been described in humans (4, 5). The 16-kDa icIL-1ra3 isoform arises by translational initiation at an internal methionine codon within the sequence common to all IL-1ra mRNAs (6, 7, 8). Intracellular IL-1ra3 is unique in that it binds to IL-1Rs ∼5-fold less avidly than do the other IL-1ra isoforms and presumably functions less efficiently as a receptor antagonist of IL-1 (7). While sIL-1ra has been well studied, the functions of the intracellular variants remain unknown. One study proposes that icIL-1ra1 may function intracellularly to reduce the half-life of IL-1-induced mRNAs (9). Intracellular IL-1ra1 may have a unique role in resolving the inflammation of synovial tissues during collagen-induced arthritis (10). The relative contributions of the different IL-1ra isoforms to the in vivo regulation of inflammatory and immune responses remain largely unresolved. We undertook an analysis of IL-1ra mutant mice, including epistasis/genetic rescue experiments, to investigate the contributions of the different isoforms to various experimental paradigms.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Murine protein isoforms of IL-1ra. A, Schematic diagram showing the relationships between the murine IL-1ra protein isoforms. Shared sequences are in black, those unique to pro-sIL-1ra (namely the signal peptide) are in gray, those unique to icIL-1ra1 (alternate exon 1) are in white, and the N-terminus that is deleted from icIL-1ra3 is hatched. B and C, Detection of the various proteins isoforms by Western blot of liver proteins from mice challenged with LPS (B) and skin proteins from unchallenged mice (C) of wt, rako, ratg, and rako, ratg mutants. The different isoforms of IL-1ra were assigned based on size relative to m.w. markers and recombinant sIL-1ra (R&D Systems), partial sequencing, and tissue distribution.

Our earlier work demonstrated that both elimination and overexpression of IL-1ra alters murine resistance to endotoxic shock (LPS) and infection with Listeria monocytogenes (11). However, these results presented an apparent paradox compared with the report that ablation of IL-1 signaling in IL-1RI-null mice did not alter their resistance to either LPS or listeriosis (on a C57BL/6J background) (12). How could changes in levels of the receptor antagonist affect responses that complete elimination of the receptor did not? While experimental protocol or strain differences might account for this discrepancy, another possible explanation is that IL-1ra might work through another receptor of the IL-1R family. Presently, the IL-1 family consists of 10 receptors and 10 ligands, many of which remain orphans (13). To resolve this paradox, we performed genetic epistasis experiments using mice with alterations in the IL-1R/IL-1ra system.

Epistasis is a genetic method used to study the interaction between two or more genes that control a single phenotype. Animals with mutations in each gene are mated, and the phenotypes of the offspring are analyzed. If one mutant gene masks the phenotype of a second mutant gene, then the first gene is considered to be epistatic to the second. Epistasis tests reveal whether the two gene products function in the same or parallel pathways and can further establish the hierarchical relationship, if any, that exists between them. We employed these methods to investigate the interrelationships between the IL-1RI and the different isoforms of IL-1ra using genetically manipulated strains of mice that lack all isoforms of IL-1ra (rako), mice that overexpress the mRNA for sIL-1ra only (ratg), and mice that lack the IL-1RI (RIko). We found that the deletion of IL-1RI as well as overexpression of the mRNA of sIL-1ra via a transgene are epistatic to deletion of all IL-1ra isoforms. Therefore, the sIL-1ra mRNA splice variant, which encodes both sIL-1ra and icIL-1ra3 isoforms, is sufficient to regulate all aspects of IL-1ra biology investigated. The roles of the intracellular splice variants remain unknown. Our results also show that the functions of IL-1ra in development, inflammation, and infection are dependent upon the presence of a functional IL-1RI; there is no other receptor.

Materials and Methods

Mice

As described in detail previously (11, 12), the single-mutant mouse strains used in these experiments are mice that lack IL-1RI (RIko), mice that lack all forms of IL-1ra (rako), and mice that hemizygously carry a transgene that encodes the sIL-1ra mRNA under control of its endogenous promoter (ratg). The ratg line used for these experiments has been previously referred to as T14. Double mutants were generated by crossing the single-mutant strains to create founders for the various strains. Briefly, the following matings were used to generate mice for experiments: RIko from −/− × −/− or +/− × −/− or +/− × +/−; rako from +/− × +/− (because −/− are infertile; see below); ratg from T14/o × +/+; rako, RIko from +/−, +/− × +/−, +/− or −/−, −/− × −/−, −/− or −/−, −/− × +/−, −/− or −/−, −/− × −/−, +/−; rako, ratg from −/−, T14/o × +/−, o/o; and ratg, RIko from T14/o, +/− × o/o, −/−. Wild-type (wt) controls were either littermates of ratg hemizygotes, littermates of rako mice, or occasionally the offspring of wt sibling matings. Genotyping was performed by PCR as previously described (11). All mice used in these experiments were backcrossed to C57BL/6J genetic backgrounds for ≥10 generations, bred in a specific-pathogen-free facility, and handled in accordance with institutional guidelines.

Monitoring of development/homeostasis

For the monitoring of postnatal developmental abnormalities in the mutant mice, littermates were caged together (three or four mice per cage) and allowed access to food and water ad libitum. Once a week, from 3–52 wk of age, mice were weighed and scored for the presence of sickness symptoms by an investigator who was blinded to the genotypes of the mice (n = 14–36/genotype/sex). To judge sickness, a scale of 0–10 was used to access both the number and the severity of sickness symptoms (including lethargy, piloerection, hunched posture, etc.), with 0 being no abnormalities, and 10 being moribund/dead. Fertility was ascertained by mating mutant mice and littermate controls starting at 6–7 wk of age with proven breeders (n = 10/genotype/sex).

Models of septic shock and listeriosis

Endotoxic shock was induced as previously described using LPS from Salmonella typhimurium (Sigma, St. Louis MO) at 10 μg/g administered i.p. (11). For studying primary listeriosis, L. monocytogenes EGD was injected i.v. at a dose of 1.0 × 106 CFU in 100 μl. Bacteria were enumerated by homogenization of organs in sterile PBS and plating serial log dilutions (14). For both challenge experiments, age-matched mice were inoculated on the same day, and survival was monitored for a total of 7 days postchallenge (n = 5–15/genotype/sex). The results reported are cumulative from three to five repeat experiments.

Analysis of blood and serum

Serum collection and blood analysis were performed as previously described (11, 14). ELISAs were performed as previously described and followed the manufacturers’ suggested protocols using the following Abs or kits: polyclonal goat anti-mIL-1ra (R&D Systems, Minneapolis, MN); DuoSet kits for IL-1β, IL-10, and TNF-α (R&D Systems); and OptEIA for IFN-γ (BD PharMingen, San Diego, CA).

Protein isolation and immunoblotting

For protein isolation, we used a modification of the TRIzol reagent protocol (Life Technologies, Gaithersburg, MD). Briefly, murine tissues were homogenized in TRIzol reagent. Following RNA isolation and removal of DNA, the proteins were isopropanol-precipitated, washed once in 0.3 M guanidine HCl/95% ethanol, and then resuspended in 6 M guanidine HCl. After dialysis overnight at 4°C with three changes of 10 mM Tris-HCl (pH 7.0) using Slide-A-Lyzer cassettes (10-kDa Mr cut-off; Pierce, Rockford, IL), the dialysate was collected and cleared by centrifugation (10,000 × g, 15 min, 4°C). The protein concentration of the resulting supernatant, which contained all the isoforms of IL-1ra (data not shown), was quantitated using the Bradford assay kit (Bio-Rad, Hercules, CA). For immunoblot analysis, 20 μg total protein was loaded on a 17.5% polyacrylamide gel and transferred to polyvinylidene difluoride membranes (Bio-Rad). Membranes were blocked for 1–2 h at room temperature in 10% nonfat dry milk in PBS/Tween, washed, incubated with 0.2 μg/ml biotinylated polyclonal goat anti-mouse IL-1ra Ab (R&D Systems) for 1 h at room temperature, washed again, and finally incubated with streptavidin-HRP (1/1,000 dilution; Amersham Pharmacia Biotech, Piscataway, NJ). Positive signal was visualized using ECL detection reagents (Amersham Pharmacia Biotech) following the manufacturer’s recommended protocol.

FACS analysis

Single-cell suspensions from thymi, spleens, and bone marrows, pooled from femur and tibia, were isolated from mutant and wt mice following standard protocols. After lysis of RBC, 106 cells were stained for 30 min with the appropriate combination of mAbs. Cells were washed (3% FCS and 0.1% sodium azide/PBS), stained with secondary reagents when necessary for 30 min, washed again, and analyzed with a FACSCalibur cytometer (BD Biosciences, San Diego CA). The mAbs used for staining were anti-CD45R/B220-PE (RA3-6B2), anti-CD3-FITC (17 A2), anti-CD8a-PerCP (Ly-2/53-6.7), anti-CD4-FITC (L3T4/RM4-5), anti-CD69-PE (H1.2F3), and anti-γδ TCR-biotin (GL3; all from BD PharMingen), and anti-Mac-1-biotin (M1/70) and anti-IgM-allophycocyanin (a gift from G. Siu). For the biotin-conjugated mAbs, the secondary staining reagent used was streptavidin-PE (BD PharMingen).

Results

Development and homeostasis

The rako mice lack all IL-1ra isoforms (11). They show abnormal development, including postnatal runting, reduced fertility, and early mortality from an unknown cause. Individual variability exists as to age of onset, symptom progression, and age of death. Nevertheless, certain generalizations can be made. The first detectable symptom, at 5–6 wk of age, is postnatal runting caused by failure to gain weight, primarily body fat (Fig. 2⇓) (15). At the same time, although otherwise asymptomatic, rako mice have an altered cellular profile, including pronounced neutrophilia and mild leukocytosis (Table I⇓). At 8–10 wk of age, rako mice have normal thymic cell populations, but alterations in some splenic cell types, specifically an increase in both γδ T cells (2.15 vs 1.56% for rako vs wt mice, respectively; n = 7 females/genotype; p = 0.03, by Student’s t test) and Mac-1+ cells (16.5 vs 14.2%; p = 0.02). Mac-1+ cells are also increased in the bone marrow of rako mice (42.5 vs 28.4%; n = 4 females/genotype; p = 0.02). Similar altered cellular profiles are present in rako males. Young adults are also subfertile; 50% of males and 30% of females were able to reproduce compared with 90–100% of wt and heterozygous littermates (n = 10/sex/genotype).

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

Postnatal growth curves of rako mice and demonstration of genetic rescue by both RIko and ratg. Shown are the average weekly weights of males (A) and females (B) from 14–36 mice of each genotype. The rako vs wt weights differ significantly starting at 5 wk of age; those of rako, RI +/− vs wt differ significantly starting at 7 wk of age.

View this table:
  • View inline
  • View popup
Table I.

Developmental abnormalities in mutant mice

As they age, rako mice become symptomatic, with piloerection, mild weight loss, and other common indications of illness (age when 50% are afflicted: females, 14 wk (n = 33); males, 17 wk (n = 36)). Mice at this stage also become 100% infertile. In a long term study, only 40% (10 of 25) of rako females and 43% (15 of 35) of rako males survived for 1 yr, compared with 100% survival of wt mice (19 of 19 females, 18 of 18 males). We have been unable to identify the ultimate cause of the early mortality of our IL-1ra knockout mice. The results of extensive histopathology, serology tests, and other analyses have not revealed any specific defect sufficient to account for the observed mortality rate.

We have taken a genetic epistasis approach to investigate the mechanism of action of the lack of IL-1ra on development and homeostasis. We constructed rako, RIko double mutants. RIko, which is developmentally normal, is epistatic to rako; deleting the type I receptor fully rescues the developmental phenotypes of rako mice (Fig. 2⇑ and Table I⇑). Further, the double-mutant IL-1ra−/−, IL-1RI+/− displays a partially dominant epistatic phenotype. As shown in Fig. 2⇑, removing a single RI allele restores rako halfway to wt weights, while removal of both alleles (rako, RIko) completely restores them. Removing a single RI allele also delays, rather than prevents, the onset of infertility and sickness symptoms (age of 50% affliction: females, 21 wk (n = 18); males, 27 wk (n = 16)) and improves 1-yr survival (64% (9 of 14) females and 92% (11 of 12) males; compare above). The single-mutant IL-1RI+/− is phenotypically wt, and there is no difference in phenotype of the IL-1ra−/−, IL-1RI+/− mutants that correlates with parental inheritance of wt or knockout RI allele, i.e., no imprinting or other epigenetic inheritance mechanism is suggested (data not shown). Taken together, these data indicate that the developmental abnormalities seen in the rako mice are dependent upon the presence as well as the gene dosage of the IL-1RI.

The double-mutant rako, ratg was also generated by crossing the two IL-1ra mutant strains. These rako, ratg doubles show the same developmental phenotype as the ratg parental strain, which is that of wt. Thus, ratg is epistatic to rako. The developmental phenotype, including runting, neutrophilia, fertility, and earlier mortality, can be rescued by overexpression of the sIL-1ra splice variant mRNA (Fig. 2⇑, Table I⇑, and data not shown).

To investigate more thoroughly which isoform of IL-1ra was responsible for this complete dominant epistasis, we analyzed the IL-1ra protein isoforms present in the various mutant mice. Both sIL-1ra and icIL-1ra3 isoforms were detected in the livers of all mice except rako, while the icIL-1ra1 isoform was not present in rako or rako, ratg mutants (Fig. 1⇑). This demonstrates that the sIL-1ra mRNA encoded by the transgene produces both sIL-1ra and icIL-1ra3. Therefore, the genetic epistasis we observed could be caused by either one or both of these isoforms. Our results also show that the alternative splice variant, icIL-1ra1, does not play an essential role in the developmental processes affected by the deletion of IL-1ra.

Further, our results suggest that sIL-1ra mRNA, not icIL-1ra1 mRNA, is the predominant source of icIL-1ra3 in vivo. Intracellular IL-1ra3 is coexpressed with sIL-1ra in the liver following LPS administration, but icIL-1ra3 is not coexpressed with icIL-1ra1 in the skin of unstimulated mice (Fig. 1⇑). After LPS administration, wt mice express all isoforms of IL-1ra in the skin, while rako, ratg mice express only sIL-1ra and icIL-1ra3 (data not shown). Therefore, either icIL-1ra3 is expressed exclusively from sIL-1ra mRNA or the alternative translation of all IL-1ra mRNAs is induced by systemic LPS administration, which is required to induce the expression of sIL-1ra. Tissue and stimulus-specific factors or the different upstream mRNA sequences might regulate this differential expression. Similar conclusions have recently been drawn regarding the expression of icIL-1ra3 from studies of transgenic mice constitutively overproducing human IL-1ra isoforms (16).

Responses to infectious and inflammatory challenges

As described in the introduction, the differences reported for the phenotype of ratg vs that of RIko created an apparent paradox that questioned whether IL-1ra functions exclusively at the IL-1RI and whether IL-1 is essential for the host response to infection and inflammation. To investigate this, we backcrossed both ratg and RIko mutants to the C57BL/6J strain for at least 10 generations and examined their responses to models of infection and inflammation side-by-side, along with wt littermate controls. In our hands, infection with the intracellular pathogen, L. monocytogenes (106 i.v., strain EGD) shows that both ratg and RIko differ from wt in survival and titers. Similarly, in a model of septic shock (i.p. administration of 10 μg/g LPS from S. typhimurium) both mutants were nearly identical in affording protection from lethality compared with wt mice (Table II⇓). Thus, on a C57BL/6J genetic background, overexpressing IL-1ra has the same effect as removing IL-1RI, supporting the view that IL-1 signaling is essential in promoting clearance of bacterial infections but is detrimental to survival after systemic inflammatory challenge.

View this table:
  • View inline
  • View popup
Table II.

Responses of mutant mice to infectious and inflammatory challenge

We have also determined the survival of double-mutant mice after i.p. administration of 10 μg/g LPS and after infection with 106 CFU L. monocytogenes (Table II⇑). The results show that RIko is epistatic to rako; the double mutant has the same survival rate as the RIko mutant alone. The same is true for the rako, ratg double mutant; the double mutant has the phenotype of the ratg parent. Overall, these data indicate that the sIL-1ra splice variant mRNA is sufficient to regulate inflammatory and infectious responses, and that its function is dependent upon the presence of the type I receptor. Finally, we constructed a ratg, RIko double-mutant strain. It has survival rates nearly identical with each of the parental strains that are themselves identical. Additive effects are not seen in this double mutant, re-enforcing the conclusion that the gene products encoded by the sIL-1ra transgene function only through IL-1RI and that there is no other target for IL-1ra.

Cytokine profile during septic shock

We previously reported parallel IL-1 and IL-1ra protein levels in serum following LPS administration, i.e., higher in the IL-1ra overexpressors and lower in the knockouts compared with wt mice (11). These in vivo results were counterintuitive, because earlier experiments had implicated IL-1 in an autoinduction, self-amplifying cascade (17, 18, 19, 20). We analyzed other cytokine profiles during sepsis in all single- and double-mutant strains to establish whether the parallel serum accumulation of IL-1 and IL-1ra is confined to the IL-1 system.

Sera were collected at 0, 1, 3, 8, and 16 h after administration of 10 μg/g LPS and were analyzed by ELISA to determine the levels of IL-1β, IL-1ra, TNF-α, IFN-γ, and IL-10. As presented in Table II⇑, the parallel regulation of IL-1 and IL-1ra was observed in all IL-1 system mutants, with peak levels of both cytokines elevated in the RIko and ratg mutants, and both diminished in the rako mutants, compared with wt controls. The levels of TNF-α, IFN-γ, and IL-10 were not different from those in wt throughout the inflammatory response in any mutant strain (data not shown). These results indicate that the parallel regulation of serum cytokine levels is confined to the IL-1 family of ligands. The analysis of the double mutants again shows that RIko and ratg are epistatic to rako, indicating that the observed phenotypes reflect the in vivo activity of the proteins made by the sIL-1ra splice variant acting through the type I receptor.

Discussion

The rako mice, on a C57BL/6J strain background, show distinct developmental phenotypes: runting; altered cellular profiles in the blood, bone marrow, and spleen; infertility; and early death. Extensive histopathological and other analyses have not revealed an underlying cause of these defects beyond the lack of IL-1ra. Some indicators of mild chronic inflammation exist, but no dramatic pathology has been seen that might account for the early mortality. The rako mouse is a sensitized strain that has generalized ill health and a failure to thrive, pointing to an essential role for IL-1ra in the maintenance of homeostasis, but the expression of disease symptoms can be highly dependent upon modifying genes that vary among different mouse strains. On other genetic backgrounds, IL-1ra deletion causes specific spontaneous inflammatory disorders, namely arthritis (in a BALB/c strain) and arteritis (in an MF1 outbred strain) (21, 22). These disorders are not seen on the C57BL/6J strain. The only phenotype independent of strain background is the postnatal runting. On the C57BL/6J strain, we have demonstrated that IL-1ra deficiency causes decreased fertility and altered leukocyte profiles. That a lack of IL-1ra increases the Mac-1+ and γδ T cell populations is consistent with the known activities of IL-1 as a cofactor for the proliferation and activation of both these cell types (1, 23, 24).

Eliminating the receptor (RIko) rescues rako developmental phenotypes. This indicates that IL-1ra functions during development depend upon the presence of the type I receptor. It further demonstrates that the IL-1 system functions during normal development and homeostasis and is sensitive to the gene dosage levels of IL-1RI expression, because IL-1ra−/−, IL-1RI+/− double mutants have intermediate phenotypes. Our results also show that the rako developmental phenotype can be suppressed by overexpression of the sIL-1ra splice variant mRNA from a transgene. It should be noted that all relevant controls, ratg, RIko, IL-1ra+/−, and IL-1RI+/− mutants, are phenotypically indistinguishable from wt mice in development and adult homeostasis. That IL-1ra heterozygotes are developmentally normal suggests that IL-1ra is overabundant in the unchallenged wt mouse. Consequently, overactive IL-1 signaling (rako) presents a greater danger to overall health than does elimination of IL-1 signaling (RIko and the IL-1α/β double knockouts) (12, 25, 26).

When we began these studies, a paradox existed because the literature ascribed different phenotypes to the ratg and RIko mice that could have indicated that IL-1ra has another target in addition to the IL-1RI (see above). Overall, our results eliminate the paradox. On a C57BL/6J genetic background (n ≥ 10), both ratg and RIko mutants were virtually identical in conferring protection against septic shock and increasing susceptibility to listeriosis. These results differ from those previously published and may be due to differences in genetic background (C57BL/6J for 10 generations vs mixed B6, 129; or B6, CBA; and C57BL/6J for five generations) or to differences in experimental methodology (i.p. administration of 10 μg/g LPS from S. typhimurium vs 40 μg/g LPS from Escherichia coli for septic shock, and 106 vs 104 CFU for listeriosis). Whatever the exact explanation, our results uphold the view that IL-1 signaling is an essential regulator of survival in response to infectious and inflammatory stimuli. Reducing the level of IL-1 signaling, by elimination of the receptor (RIko) or by increased expression of IL-1ra (ratg), increases resistance to systemic inflammation and inhibits innate immune responses. Our genetic analysis also validates the conclusions of previous studies using less direct methods, including Ab neutralization and administration of exogenous recombinant proteins, demonstrating the essential roles of IL-1 and IL-1ra in these processes (reviewed in Ref. 27). It also raises the possibility that excess IL-1ra, as prescribed for treating severe rheumatoid arthritis, might increase susceptibility to infection.

Our analysis of the cytokine network induced by LPS administration reveals that IL-1 and IL-1ra serum levels are coregulated in vivo even though their expression is differentially regulated in vitro. In all the mutant mice examined this coregulation is confined to IL-1 family of cytokines. This suggests that the parallel levels of IL-1 and IL-1ra reflect an accumulation of proteins in serum due to competition for receptor binding that would reduce the level of free cytokine in the bloodstream, rather than an alteration in de novo protein/mRNA synthesis that might indicate a global regulation of the cytokine network itself. Further, these results demonstrate that despite its potential for autoinduction, IL-1 is not an obligate inducer of itself in vivo following LPS administration, because IL-1β levels in both the RIko and ratg mutants (and double mutants) reach or exceed those of wt mice. Finally, maintaining the balance between IL-1 and IL-1ra levels is critical to the proper function of the inflammatory response in vivo. Therefore, it is necessary to measure the IL-1/IL-1ra ratio, and not simply the absolute levels of IL-1, to determine accurately the involvement of IL-1 in the pathogenesis of any disease state.

In all the experimental paradigms we examined, both the ratg and RIko phenotypes were epistatic to the rako phenotype. These results demonstrate that there is no function of IL-1ra independent of the type I receptor and that this function can be fulfilled solely by overexpression of sIL-1ra mRNA. We have been unable to identify any essential role for the icIL-1ra splice variants. However, overexpression of sIL-1ra in ratg mice may mask a contributory role of icIL-1ra during infectious and inflammatory processes, as the ratg phenotype, which differs from that of wt, is seen in the rako, ratg double mutant. Also, the icIL-1ra3 isoform is expressed from the sIL-1ra transgene and may functionally substitute for the alternative splice variants. The question remains of whether sIL-1ra, icIL-1ra3, or both isoforms affect the observed genetic rescue. Our results from the rako, RIko and ratg, RIko double mutants establish that IL-1ra functions exclusively through the IL-1RI. This must be true for both the secreted and intracellular forms. Clearly, intracellular forms must function either by a unique release pathway or be targeted to intracellular functions dependent on the activation of the IL-1RI. However, the simplest model to explain the rako phenotype is a lack of inhibition of IL-1 by sIL-1ra and a resulting chronic overstimulation of the IL-1RI.

Acknowledgments

We thank Dr. Jacques Peschon at Immunex (Seattle, WA) for providing the IL-1RI knockout mice and for critical review of the manuscript, and Dr. Gerry Siu for providing Abs and help for FACS analysis. We are especially grateful to Melissa Foster and Kyung-Hyun Park Min for excellent technical assistance. We also thank Dr. Barth Grant and other members of the Hirsh laboratory for helpful discussions.

Footnotes

  • ↵1 This work was supported by National Institutes of Health Grant AI62861.

  • ↵2 Address correspondence and reprint requests to Dr. David Hirsh, Department of Biochemistry and Molecular Biophysics, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032. E-mail address: dih1{at}columbia.edu

  • ↵3 Abbreviations used in this paper: IL-1RI, type I IL-1R; IL-1ra, IL-1R antagonist; icIL-1ra, intracellular IL-1ra.

  • Received March 22, 2002.
  • Accepted April 24, 2002.
  • Copyright © 2002 by The American Association of Immunologists

References

  1. ↵
    Dinarello, C. A.. 1996. Biologic basis for interleukin-1 in disease. Blood 87: 2095
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Greenfeder, S. A., P. Nunes, L. Kwee, M. Labow, R. A. Chizzonite, G. Ju. 1995. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J. Biol. Chem. 270: 13757
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Arend, W. P., M. Malyak, C. J. Guthridge, C. Gabay. 1998. Interleukin-1 receptor antagonist: role in biology. Annu. Rev. Immunol. 16: 27
    OpenUrlCrossRefPubMed
  4. ↵
    Muzio, M., N. Polentarutti, M. Sironi, G. Poli, L. De Gioia, M. Introna, A. Mantovani, F. Colotta. 1995. Cloning and characterization of a new isoform of the interleukin 1 receptor antagonist. J. Exp. Med. 182: 623
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Muzio, M., N. Polentarutti, F. Facchetti, G. Peri, A. Doni, M. Sironi, P. Transidico, M. Salmona, M. Introna, A. Mantovani. 1999. Characterization of type II intracellular IL-1 receptor antagonist (IL-1ra3): a depot IL-1ra. Eur. J. Immunol. 29: 781
    OpenUrlCrossRefPubMed
  6. ↵
    Holtkamp, G. M., A. F. de Vos, A. Kijlstra, R. Peek. 1999. Expression of multiple forms of IL-1 receptor antagonist (IL-1ra) by human retinal pigment epithelial cells: identification of a new IL-1ra exon. Eur. J. Immunol. 29: 215
    OpenUrlCrossRefPubMed
  7. ↵
    Malyak, M., J. M. Guthridge, K. R. Hance, S. K. Dower, J. H. Freed, W. P. Arend. 1998. Characterization of a low molecular weight isoform of IL-1 receptor antagonist. J. Immunol. 161: 1997
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Malyak, M., M. F. Smith, Jr, A. A. Abel, K. R. Hance, W. P. Arend. 1998. The differential production of three forms of IL-1 receptor antagonist by human neutrophils and monocytes. J. Immunol. 161: 2004
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Watson, J. M., A. K. Lofquist, C. A. Rinehart, J. C. Olsen, S. S. Makarov, D. G. Kaufman, J. S. Haskill. 1995. The intracellular IL-1 receptor antagonist alters IL-1-inducible gene expression without blocking exogenous signaling by IL-1β. J. Immunol. 155: 4467
    OpenUrlAbstract
  10. ↵
    Gabay, C., L. Marinova-Mutafchieva, R. O. Williams, J. P. Gigley, D. M. Butler, M. Feldmann, W. P. Arend. 2001. Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis. Arthritis Rheum. 44: 451
    OpenUrlCrossRefPubMed
  11. ↵
    Hirsch, E., V. M. Irikura, S. M. Paul, D. Hirsh. 1996. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc. Natl. Acad. Sci. USA 93: 11008
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Glaccum, M. B., K. L. Stocking, K. Charrier, J. L. Smith, C. R. Willis, C. Maliszewski, D. J. Livingston, J. J. Peschon, P. J. Morrissey. 1997. Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. J. Immunol. 159: 3364
    OpenUrlAbstract
  13. ↵
    Dunn, E., J. E. Sims, M. J. Nicklin, L. A. O’Neill. 2001. Annotating genes with potential roles in the immune system: six new members of the IL-1 family. Trends Immunol. 22: 533
    OpenUrlCrossRefPubMed
  14. ↵
    Irikura, V. M., E. Hirsch, D. Hirsh. 1999. Effects of interleukin-1 receptor antagonist overexpression on infection by Listeria monocytogenes. Infect. Immun. 67: 1901
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Josephs, M. D., C. C. Solorzano, M. Taylor, J. J. Rosenberg, D. Topping, A. Abouhamze, S. L. D. Kackay, E. Hirsch, D. Hirsh, M. Labow, et al 2000. Modulation of the acute phase response by altered expression of the IL-1 type 1 receptor or IL-1ra. Am. J. Physiol. 278: R824
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Gabay, C., J. Gigley, J. Sipe, W. P. Arend, G. Fantuzzi. 2001. Production of IL-1 receptor antagonist by hepatocytes is regulated as an acute-phase protein in vivo. Eur. J. Immunol. 31: 490
    OpenUrlCrossRefPubMed
  17. ↵
    Dinarello, C. A., T. Ikejima, S. J. C. Warner, S. F. Orencole, G. Lonnemann, J. G. Cannon, P. Libby. 1987. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J. Immunol. 139: 1902
    OpenUrlAbstract
  18. ↵
    Warner, S. J. C., K. R. Auger, P. Libby. 1987. Interleukin 1 induces interleukin 1. II. Recombinant human interleukin 1 induces interleukin 1 production by adult human vascular endothelial cells. J. Immunol. 139: 1911
    OpenUrlAbstract
  19. ↵
    Granowitz, E. V., E. Vannier, D. D. Poutsiaka, C. A. Dinarello. 1992. Effect of interleukin-1 (IL-1) blockade on cytokine synthesis. II. IL-1 receptor antagonist inhibits lipopolysaccharide-induced cytokine synthesis by human monocytes. Blood 79: 2364
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Granowitz, E. V., B. D. Clark, E. Vannier, M. V. Callahn, C. A. Dinarello. 1992. Effect of interleukin-1 (IL-1) blockade on cytokine synthesis. I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. Blood 79: 2356
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Horai, R., S. Saijo, H. Tanioka, S. Nakae, K. Sudo, A. Okahara, T. Ikuse, M. Asano, Y. Iwakura. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191: 313
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Nicklin, M. J. H., D. E. Hughes, J. L. Barton, J. M. Ure, G. W. Duff. 2000. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J. Exp. Med. 191: 303
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Skeen, M. J., H. K. Ziegler. 1995. Activation of γδ T cells for production of IFN-γ is mediated by bacteria via macrophage-derived cytokines IL-1 and IL-12. J. Immunol. 154: 5832
    OpenUrlAbstract
  24. ↵
    Skeen, M. J., H. K. Ziegler. 1993. Intercellular interactions and cytokine responsiveness of peritoneal α/β and γ/δ T cells from Listeria-infected mice: synergistic effects of interleukin 1 and 7 on γ/δ T cells. J. Exp. Med. 178: 985
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Labow, M., D. Shuster, M. Zetterstrom, P. Nunes, R. Terry, E. B. Cullinan, T. Bartfai, C. Solorzano, L. L. Moldawer, R. Chizzonite, et al 1997. Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. J. Immunol. 159: 2452
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Horai, R., M. Asano, K. Sudo, H. Kanuka, M. Suzuki, M. Nishihara, M. Takahashi, Y. Iwakura. 1998. Production of mice deficient in genes for interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 receptor antagonist shows that IL-1β is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 187: 1463
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Arend, W. P., C. J. Guthridge. 2000. Biological role of interleukin 1 receptor antagonist isoforms. Ann. Rheum. Dis. 59: (Suppl. 1):i60
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Immunology: 169 (1)
The Journal of Immunology
Vol. 169, Issue 1
1 Jul 2002
  • Table of Contents
  • About the Cover
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Epistatic Interrelationships of IL-1, IL-1 Receptor Antagonist, and the Type I IL-1 Receptor
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Epistatic Interrelationships of IL-1, IL-1 Receptor Antagonist, and the Type I IL-1 Receptor
Vera M. Irikura, Mouna Lagraoui, David Hirsh
The Journal of Immunology July 1, 2002, 169 (1) 393-398; DOI: 10.4049/jimmunol.169.1.393

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Epistatic Interrelationships of IL-1, IL-1 Receptor Antagonist, and the Type I IL-1 Receptor
Vera M. Irikura, Mouna Lagraoui, David Hirsh
The Journal of Immunology July 1, 2002, 169 (1) 393-398; DOI: 10.4049/jimmunol.169.1.393
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Lung dysfunction in a mouse model of inflammation is dependent on T-cell-independent IL-13 expression (54.18)
  • TSG-6, a new protein ligand for CXCL8, modulates the activity of this pro-inflammatory chemokine (54.12)
  • Anti-inflammatory and anti-bacterial effect of polyacetylene compound from Cirsium japonicum var. ussuriense (54.19)
Show more Inflammation

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2021 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606